<unk>  functions as a prodrug to phenmetrazine; approximately 30 percent of an oral dose is converted into it.<unk>  can essentially be thought of as an extended-release formulation of phenmetrazine with less potential for abuse.<unk>  is an anorectic drug which acts as a norepinephrine-dopamine releasing agent (NDRA). As an amphetamine congener, its structure incorporates the backbone of methamphetamine, a potent CNS stimulant. While the addition of an N-methyl group to amphetamine significantly increases its potency and bioavailability, methylation of phenmetrazine renders the compound virtually inactive. However,<unk>  is a prodrug for phenmetrazine which acts as the active metabolite.<unk>  possesses preferable pharmacokinetics over phenmetrazine as a therapeutic agent because its metabolization by demethylases produces a more steady and prolonged exposure of active drug within the body. This decreases abuse potential as the peak blood-concentration of active phenmetrazine that's produced from a single dose of<unk>  is lower than a single therapeutically equivalent dose of phenmetrazine. Indicated as a short-term secondary treatment for exogenous obesity,<unk>  immediate-release 35mg tablets are typically consumed one hour before meals, not to exceed three doses daily.<unk>  is also manufactured as a 105mg extended-release capsule for once daily dosing, typically consumed 30 to 60 minutes before a morning meal. Whereas the immediate-release formulation has a maximum daily dosage of 210mg (6 tablets), the extended-release capsules have a maximum daily dosage of 105mg (one capsule).
Phendimetrazine
Safrazine
Chlorotrianisene
Cariprazine
Pseudophenmetrazine
Desmethylchlorotrianisene
Dibenzofuran
Michellamine